Cotinga Pharmaceuticals Inc.
Cotinga Pharmaceuticals Inc. (COTQF) Revenue
Annual & quarterly revenue history · segment & region breakdown
COTQF · revenue · updated Jun 9, 2026
Core revenue metrics
Trailing 12 monthsCotinga Pharmaceuticals Inc. trailing twelve-month (TTM) revenue is $0.00B, an increase of 0.00% year-over-year from $0.00B in FY2019.
Revenue trend
2019 – 2013 · AnnualRevenue history
| Fiscal year end | Revenue | Change | Growth |
|---|---|---|---|
| 2019-04-30 | $0.00B | +$0.00B | — |
| 2018-04-30 | $0.00B | +$0.00B | — |
| 2017-04-30 | $0.00B | +$0.00B | — |
| 2016-04-30 | $0.00B | +$0.00B | — |
| 2015-04-30 | $0.00B | +$0.00B | — |
| 2014-04-30 | $0.00B | -$0.00B | -100.00% |
| 2013-04-30 | $0.00B | — | — |
About Revenue & Reporting
Revenue (also called sales, net sales, or turnover) is the total income Cotinga Pharmaceuticals Inc. receives from its business operations before deducting any costs or expenses. It is the top line of the income statement. Unlike net income or earnings, revenue does not account for operating costs, taxes, interest, or depreciation.
Cotinga Pharmaceuticals Inc. reports revenue on a fiscal year ending Dec 31 basis under US GAAP, denominated in USD.
Data sourced from Cotinga Pharmaceuticals Inc.'s 10-K and 10-Q SEC filings via Financial Modeling Prep.
Frequently asked questions
COTQF revenue · 4 questionsCOTQF's trailing twelve-month (TTM) revenue is $0.00B. That is an increase of 0.00% year-over-year from $0.00B in FY2019.
▸ Source: FMP · Cotinga Pharmaceuticals Inc. SEC filings · GAAP · Cotinga Pharmaceuticals Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 9, 2026